[Hodgkin's lymphoma associated with thrombotic microangiopathy: case report and literature review]

We report a 51-year-old woman, who presented thrombotic microangiopathy associated with Hodgkin's lymphoma relapse after three years of complete remission. After treatment with corticotherapy, plasmatherapy, rituximab and chemotherapy, complete remission of thrombotic microangiopathy and Hodgkin's lymphoma was observed. Our literature review notes eight cases of thrombotic microangiopathy associated with Hodgkin's lymphoma

[Chronic myeloid leukemia and inhibitors of tyrosine kinase]

Chronic myeloid leukemia is a hematological malignancy in the group of myeloproliferative syndromes. It is characterized by the presence of an acquired genetic abnormality at the hematopoietic stem cells, the Philadelphia chromosome. Inhibitors of tyrosine kinase, whose leader is imatinib, has profoundly changed the therapeutic management and prognosis of this malignancy. The failure of imatinib treatment is due to resistance mechanisms that are not all fully characterized. However, cross and multiple resistance remain difficult to treat and require a better understanding of their mechanisms to overcome residual disease in the near future. The persistence of a long term residual disease associated with the presence of quiescent leukemic cells, and the occurrence of relapse led to the development of second and third generation inhibitors tyrosine kinase and the combination of these inhibitors with therapeutic immunomodulators such as interferon alpha, or vaccination protocols are discussed. The purpose of this review is to update on the molecular abnormalities found in chronic myeloid leukemia with emphasis on mechanisms of imatinib resistance and the current therapeutic strategy in the era of new generations of inhibitors of tyrosine kinase

[ myelodysplastic syndromes]

There are a group of clonal hematologic disorder, which combine ineffective hematopoiesis and evolution to acute myeloid leukaemia. We conducted a 7 years retrospective. In order to specify the typology of the myelodysplastic syndromes. We included patients presented it diagnosed on the complete blood count and the myelogram between January 2001 and January 2008. Forty patients have been included [29 men, 11 women, sex-ratio 2.63], median age 62 +/- 16 years [23-85]. Nineteen patients only presented a peripheral unilineage cytopenia, fifteen patients had a bicytopnia and five presented a pancytopenia. By using the French Americano-British classification, the myelodysplastic syndromes were distributed in 27% of refractory anemias, 15% of refractory anemias with sideroblast, 25% of refractory anemias with excess of blast, 8% of refractory anemias with excess of blast in transformation, and 24% of chronic myelomonocytic leukemia. By using the criteria of the NOH, distribution is of 37% of refractory anemias [with or without sideroblast], 17% of refractory cytopenia with multilineage dysplasia [with or without sideroblast], 33% of refractory anemias with excess of blast, 3% of Myelodysplastic syndromes associated to the insulated delection 5q - and 10% of acute leukeamias. The score of Bournemouth has been calculated for every patient. The results join those of the literature. The authors will discuss the interest using of one or the other classification of that affection. They note the difficulties of diagnosis of the it needed, the limits between the various entities remain still remain badly known for most the practitioners. The need for a precise and complete diagnosis is essential in order to better classify the Myelodysplastic syndromes, and consequently to evaluate the prognosis and to make a reasoned therapeutic decision of it